Abstract

Purpose of review: Giant cell arteritis (GCA) remains a potentially blinding inflammatory vasculitis of the elderly. Because prolonged doses of corticosteroids remain the best established treatment, side-effects during treatment are common and potentially serious. This review addresses the challenges clinicians face in managing this disease. Recent findings: High-dose corticosteroids with slow tapering and close monitoring are the mainstay of treatment. Investigations into adjunctive treatment have yet to establish other agents as beneficial, but further research is ongoing with some promising results. Summary: GCA represents a challenging illness to clinicians because of its potential for causing blindness and the need for prolonged high doses of corticosteroids with their many complications.

Original languageEnglish (US)
Pages (from-to)469-475
Number of pages7
JournalCurrent Opinion in Ophthalmology
Volume26
Issue number6
DOIs
StatePublished - Oct 9 2015

Keywords

  • Giant cell arteritis
  • Statin
  • Steroid-sparing agents in GCA
  • Steroids in GCA
  • Thromboembolic drugs

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Treatment of giant cell arteritis'. Together they form a unique fingerprint.

Cite this